Advertisement

Brain Protection Against Oxygen Deficiency by Nizofenone

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 222)

Abstract

Oxygen deprivation is one of the most damaging conditions affecting the brain. When the oxygen supply to the brain is deficient, oxidative energy metabolism ceases and all related metabolic activities are drastically changed, resulting in disorder of cerebral function and tissue deterioration. Much effort has been devoted to finding suitable agents which would enable the brain to withstand oxygen deficiency (Hossmann, 1982).

Keywords

Cerebral Ischemia Middle Cerebral Artery Occlusion Oxygen Deficiency Transient Cerebral Ischemia Cerebral Energy Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson N.S. and Brain Resuscitation Clinical Trial I Study Group, 1986, Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest, New Eng. J. Med., 314: 397.Google Scholar
  2. Bazan N.G., 1970, Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain, Biochim. Biophys. Acta, 218: 1.CrossRefGoogle Scholar
  3. Chan P.H. and Fishman R.A., 1980, Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling, J, Neurochem., 35: 1004.CrossRefGoogle Scholar
  4. Gryglewski R.J., Nowak S., Kostka-Trabka E., Kusmiderski J., Dembinska-Kiec A., Bieron K., Basista M. and Blaszczyk B., 1983, Treatment of ischemic stroke with prostacyclin, Stroke, 14: 197.CrossRefGoogle Scholar
  5. Hossmann K.A., 1982, Treatment of experimental cerebral ischemia, J. Cereb. Blood Flow Metabol., 3: 275.CrossRefGoogle Scholar
  6. Izumi N. and Yasuda H., 1983, A convenient cerebral ischemia model using mice, J. Cereb, Blood Flow Metabol., 3 (Suppl. 1): 391.Google Scholar
  7. Lowry O.H. and Passonneau J.V., 1972, “A flexible system of enzymatic analysis”, Academic Press, New York.Google Scholar
  8. Michenfelder J.D., Milde J.H. and Sundt T.M.Jr., 1976, Cerebral protection by barbiturate anesthesia, Arch. Neurol., 33: 345.CrossRefGoogle Scholar
  9. Nakanishi M., Yasuda H. and Tsumagari T., 1973, Protective effect of anti-anxiety drugs against hypoxia, Life Sci., 13: 467.CrossRefGoogle Scholar
  10. Nemoto E.M., Shiu G.K., Nemmer J. and Bleyaert A.L., 1982, Attenuation of brain free fatty acid liberation during global ischemia: a model for screening potential therapies for efficacy?, J. Cereb. Blood Flow Metab., 2: 475.CrossRefGoogle Scholar
  11. Ochiai C., Asano T., Tamura A., Sano K., Fukuda T. and Nakamura T., 1981, An experimental study on the mechanism of the protective action of pentobarbital and Y-9179 against cerebral ischemia, Neurol. Med. Chir. (Tokyo), 21: 303.CrossRefGoogle Scholar
  12. Ochiai C., Asano T., Takakura K., Fukuda T., Horizoe H. and Morimoto Y., 1982, Mechanisms of cerebral protection by pentobarbital and nizofenone correlated with the course of local cerebral blood flow changes, Stroke, 13: 788.CrossRefGoogle Scholar
  13. Ohta T., Kikuchi H., Hashi K. and Kudo Y., 1986, Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study, J. Neurosurg., 64: 420.CrossRefGoogle Scholar
  14. Saito I., Asano T., Ochiai C., Takakura K., Tamura A. and Sano K., 1983, A double-blind clinical evaluation of the effect of nizofenone (Y-9179) on delayed ischemic neurological deficits following aneurysmal rupture, Neurol, Res., 5: 29.Google Scholar
  15. Siesjo B.K., 1981, Cell damage in the brain: a speculative synthesis, J. Cereb. Blood Flow Metab., 1: 155.CrossRefGoogle Scholar
  16. Smith A.L., 1977, Barbiturate protection in cerebral hypoxia, Anesthesiology, 47: 285.CrossRefGoogle Scholar
  17. Tamura A., Asano T., Sano K., Tsumagari T. and Nakajima A., 1979, Protection from cerebral ischemia by a new imidazole derivative (Y-9179) and pentobarbital: A comparative study in chronic middle cerebral artery occlusion in cats, Stroke, 10: 126.CrossRefGoogle Scholar
  18. Yasuda H., Shuto S., Tsumagari T. and Nakajima A., 1978, Protective effect of a novel imidazole derivative against cerebral anoxia, Arch. Int. Pharmacodyn. Ther., 233: 136.PubMedGoogle Scholar
  19. Yasuda H., Nakanishi M., Tsumagari T., Nakajima A. and Nakanishi M., 1979, The mechanism of action of a novel cerebral protective drug against anoxia. I. The effect on cerebral energy demand, Arch. Int. Pharmacodyn. Ther., 242: 77.PubMedGoogle Scholar
  20. Yasuda H., Shimada O., Nakajima A. and Asano T., 1981, Cerebral protective effect and radical scavenging action, J. Neurochem., 37: 934.CrossRefGoogle Scholar
  21. Yasuda H., Nakanishi M. and Izumi N., 1983, Cerebral protection by pentetrazol against hypoxia, in: “Current Problems in Epilepsy”, Baldy-Moulinier M., Ingvar D.H. and Meldrum B.S. ed., John Libbey, London, pp. 292–296.Google Scholar
  22. Yasuda H., Ochi H. and Tsumagari T., 1984, Stimulation of prostacyclin synthesis by nizofenone, Biochem. Pharmacol., 33: 2707.CrossRefGoogle Scholar
  23. Yasuda H., Kishiro K., Izumi N. and Nakanishi M., 1985, Biphasic liberation of arachidonic and stearic acids during cerebral ischemia, J. Neurochem., 45: 168.CrossRefGoogle Scholar
  24. Yoshida S., Inoh S., Asano T., Sano K., Kubota M., Shimazaki H. and Ueta N., 1980, Effect of transient ischemia on free fatty acids and phospholipids in the gerbil brain: lipid peroxidation as a possible cause of postischemic injury, J. Neurosurg., 53: 323.CrossRefGoogle Scholar
  25. Yoshida S., Inoh S., Asano T., Sano K., Kubota M., Shimazaki H., Ueta N., Yasuda H. and Shimada O., 1980, Brain free fatty acids in transient cerebral ischemia and the effect of metabolic depressants, Brain Nerve, 32: 931.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  1. 1.Research LaboratoriesYoshitomi Pharmaceutical Ind. Ltd.Fukuoka-ken 871Japan

Personalised recommendations